Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PAXIL CR vs KALEXATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.
KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.
Major depressive disorder,Obsessive-compulsive disorder,Panic disorder,Social anxiety disorder,Generalized anxiety disorder,Posttraumatic stress disorder,Premenstrual dysphoric disorder (off-label),Hot flashes (off-label)
Treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs),Treatment of giant cell arteritis in adult patients
12.5-37.5 mg orally once daily in the morning; initial dose 12.5 mg/day, titrate by 12.5 mg/day at intervals of at least 1 week to maximum 50 mg/day.
10 mg orally once daily.
The terminal elimination half-life of paroxetine (PAXIL CR) is approximately 15-20 hours. This supports once-daily dosing and requires about 5-7 days to reach steady-state concentration.
12-15 hours; prolonged in renal impairment (up to 30 hours in severe cases)
Extensively metabolized in the liver primarily via cytochrome P450 enzyme CYP2D6. Paroxetine is a potent inhibitor of CYP2D6. Metabolites are less active and are excreted in urine and feces.
KALEXATE is a monoclonal antibody; it is catabolized into small peptides and amino acids via general protein degradation pathways. No specific metabolic enzymes or pathways are involved.
Renal excretion accounts for approximately 64% of the administered dose, with 2% as unchanged parent drug and the remainder as metabolites. Fecal excretion accounts for about 36%, mostly as metabolites. Less than 1% is excreted in bile.
Primarily renal (75-80% as unchanged drug); biliary/fecal (15-20%)
Approximately 93-95% bound to plasma proteins, primarily alpha-1-acid glycoprotein and albumin.
60-70% primarily to albumin
Apparent volume of distribution (Vd/F) is approximately 3-28 L/kg, with an average of about 13 L/kg. This wide distribution indicates extensive tissue partitioning, with brain concentrations several times higher than plasma.
1.2-1.6 L/kg; indicates extensive extravascular distribution
Oral bioavailability of PAXIL CR is about 30% due to first-pass metabolism, but is lower than the immediate-release formulation (50%). Food does not significantly affect bioavailability.
Oral: 85-95%
Creatinine clearance 30-60 m L/min: use lower end of dosing range (12.5 mg/day maximum). Creatinine clearance <30 m L/min: not recommended.
GFR >= 60 m L/min: no adjustment; GFR < 60 m L/min: use not recommended.
Child-Pugh Class A or B: initial dose 12.5 mg/day, maximum 25 mg/day. Child-Pugh Class C: not recommended.
Child-Pugh A: 5 mg once daily; Child-Pugh B: 2.5 mg once daily; Child-Pugh C: not recommended.
Not approved for use in pediatric patients; safety and efficacy not established.
Not approved for pediatric use.
Initial dose 12.5 mg/day; maximum 25 mg/day. Increased sensitivity to serotonin reuptake inhibition; monitor for hyponatremia and QT prolongation.
No specific dose adjustment; monitor renal function.
Suicidality and Antidepressant Drugs: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term trials. Monitor closely for clinical worsening, suicidality, or unusual changes in behavior.
Risk of serious infections including tuberculosis, invasive fungal infections, and other opportunistic pathogens. Patients should be screened for latent tuberculosis prior to initiation. If serious infection develops, interrupt KALEXATE until infection is controlled.
Clinical worsening and suicide risk,Serotonin syndrome,Bleeding abnormalities,Activation of mania/hypomania,Seizures,Angle-closure glaucoma,Hyponatremia,Bone fractures,Discontinuation syndrome (withdrawal reactions)
Serious infections,Hepatotoxicity (elevated liver enzymes),Neutropenia,Thrombocytopenia,Lipid elevations,Gastrointestinal perforation (risk higher in patients with diverticulitis),Hypersensitivity reactions,Live vaccines should not be given concurrently
Concomitant use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI,Concomitant use with pimozide or thioridazine,Known hypersensitivity to paroxetine or any component of the formulation
Known hypersensitivity to KALEXATE or any of its excipients,Active infections including localized infections
No specific food restrictions, but avoid excessive alcohol intake. Grapefruit has not been reported to interact significantly with paroxetine.
Avoid potassium-rich foods (bananas, oranges, potatoes, spinach, tomatoes, salt substitutes). Do not mix with fruit juices containing high potassium (e.g., orange, tomato). Maintain adequate fluid intake to prevent constipation.
First trimester: Increased risk of congenital cardiovascular malformations (primarily septal defects) and persistent pulmonary hypertension of the newborn (PPHN). Third trimester: Risk of neonatal adaptation syndrome (irritability, feeding difficulties, respiratory distress) and prolonged QT interval. Late third trimester exposure may cause serotonin syndrome in neonate.
Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypernatremia) may indirectly affect fetal development. No specific teratogenic risk is documented; avoid severe maternal electrolyte imbalances.
Paroxetine is excreted into breast milk. M/P ratio is approximately 0.39. Milk levels vary; peak concentration occurs 2-4 hours post-dose. Most studies show no adverse effects in breastfed infants, but cases of irritability, poor feeding, and transient serotonin-like symptoms have been reported. Use caution; monitor infant for drowsiness, restlessness, and weight gain.
Kalexate is not absorbed from the gastrointestinal tract, so systemic concentrations are negligible. M/P ratio is not applicable. Considered compatible with breastfeeding, but monitor infant for electrolyte imbalance if maternal use is prolonged.
Paroxetine clearance may decrease in pregnancy, leading to higher plasma concentrations. However, dose adjustments are generally not routinely recommended due to limited data. Consider therapeutic drug monitoring if response is inadequate or side effects occur. The risk of birth defects with high doses (>30 mg/day) may be increased, so use lowest effective dose (12.5-37.5 mg/day CR). Avoid abrupt discontinuation; taper slowly postpartum.
Standard dosing (15-60 g orally per day) may be used in pregnancy. No pharmacokinetic changes requiring dose adjustment as the drug is not absorbed. However, monitor electrolytes more frequently due to pregnancy-related volume expansion and altered renal function.
PAXIL CR (paroxetine extended-release) has a longer half-life than immediate-release, allowing once-daily dosing but requiring 3-4 weeks for steady state. Due to its potent CYP2D6 inhibition, use caution with tamoxifen (reduces active metabolite) and with other serotonergic drugs (risk of serotonin syndrome). Discontinuation syndrome is common; taper gradually. Pregnancy category D; avoid in third trimester due to risk of persistent pulmonary hypertension of the newborn (PPHN).
Kalexate (sodium polystyrene sulfonate) exchanges sodium for potassium in the gastrointestinal tract. Onset of action is 2-12 hours. Avoid in patients with hypokalemia, severe hypernatremia, or bowel obstruction. Monitor serum potassium and sodium levels regularly. Use with caution in patients with congestive heart failure or severe edema due to sodium load. Administer orally or as a retention enema; do not mix with fruit juices containing high potassium (e.g., orange juice).
Take this medication once daily, usually in the morning with or without food. Swallow the tablet whole; do not crush, chew, or divide.,It may take several weeks to feel the full benefit; do not stop suddenly as withdrawal symptoms may occur.,Avoid alcohol while taking PAXIL CR as it can increase dizziness and drowsiness.,Inform your doctor if you are pregnant, planning to become pregnant, or breastfeeding.,Report any suicidal thoughts or unusual changes in mood immediately.,Do not take with MAO inhibitors (e.g., phenelzine) or within 14 days of stopping them.,Contact a healthcare professional if you experience symptoms of serotonin syndrome (fever, muscle stiffness, confusion, rapid heart rate).
Take this medication exactly as prescribed to lower high potassium levels.,Do not mix with orange juice or other high-potassium beverages.,Drink plenty of water with each dose to prevent constipation.,Report any signs of bowel obstruction (severe abdominal pain, vomiting, no bowel movements) immediately.,Notify your doctor if you experience irregular heartbeat, muscle weakness, or numbness/tingling.,This medication contains sodium; inform your doctor if you have heart failure or high blood pressure.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PAXIL CR vs KALEXATE, answered by our medical review team.
PAXIL CR is a SSRI Antidepressant that works by Paroxetine is a selective serotonin reuptake inhibitor (SSRI). It potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane, resulting in increased serotonin concentrations in the synaptic cleft.. KALEXATE is a SSRI Antidepressant that works by KALEXATE is a monoclonal antibody that binds to both soluble and membrane-bound human interleukin-6 (IL-6) receptors, inhibiting IL-6-mediated signaling. IL-6 is a pro-inflammatory cytokine implicated in the pathogenesis of rheumatoid arthritis and other inflammatory conditions.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PAXIL CR and KALEXATE depend on the specific clinical indication. These are both SSRI Antidepressant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PAXIL CR is: 12.5-37.5 mg orally once daily in the morning; initial dose 12.5 mg/day, titrate by 12.5 mg/day at intervals of at least 1 week to maximum 50 mg/day.. The standard adult dose of KALEXATE is: 10 mg orally once daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PAXIL CR and KALEXATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PAXIL CR is classified as Category C. First trimester: Increased risk of congenital cardiovascular malformations (primarily septal defects) and persistent pulmonary hypertension of the newborn (PPHN). Third trimester: . KALEXATE is classified as Category C. Kalexate (sodium polystyrene sulfonate) is not absorbed systemically and thus has no direct fetal exposure. However, electrolyte disturbances from maternal use (hypokalemia, hypern. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.